Advancing Non-Viral Gene Editing: CellShot® PFEP Technology and Proliva™ For Enhanced Post-Electroporation Performance

Non-viral gene delivery is rapidly transforming the landscape of cell and gene therapy, particularly in the wake of the FDA’s boxed warning on viral vector–based CAR-T products and the first approval of CRISPR based CGT, Casgevy. The CellShot® platform, powered by proprietary Partitioned Flow Electroporation (PFEP™) and Proliva™ technologies, delivers high-efficiency, thermal-damage-free transfection for both knockout and challenging knock-in applications. This innovation will contribute to overcome key bottlenecks in nuclear entry, viability retention, and process scalability, enabling advanced CRISPR and TALEN workflows for clinical and manufacturing environments.

Proprietary Proliva™ is the non-toxic delivery buffer developed to complement the PFEP™ transfection platform. By protecting subcellular organelles from electrical stress, stabilizing mitochondrial function, and reducing oxidative damage, Proliva™ significantly improves post-electroporation proliferation rates, cell viability, and efficiency. This can result in higher overall yields and more reliable performance for complex gene-editing processes in diverse biopharmaceutical gene processes, such as large donor template knock-ins.

In this webinar, we will explore the unique engineering of the PFEP™ microfluidic chamber, its impact on heat dissipation and throughput, and how Proliva™ addresses the critical challenge of organelle protection. Real-world performance data, including viability, proliferation, and efficiency metrics, will be presented alongside assay data from MitoTrackerGreen (mitochondria), JC-1/TMRE (MMP), MitoSOX (ROS), γH2AX (DSB), and cytokine analysis such as IL-2, TNF-α, CXCL10, GM-CSF. Participants will gain practical insights into optimizing non-viral gene-editing protocols for both research and GMP manufacturing settings.